Back to search results
NCT05967351

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

Enrolling by Invitation
PHASE3All AgesInterventional
Sarepta Therapeutics, Inc.
~400 participants
Updated 2026-02-06 on ClinicalTrials.gov
What's tested:delandistrogene moxeparvovec

At a glance

Recruiting sites
0 of 38 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)
Measured over Up to 10 years

Conditions

Duchenne Muscular Dystrophy

Explore related trials

Duchenne Muscular Dystrophy

NCT05967351

Where you'd take part

This study runs at 38 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinoisno site contact published

  • Arkansas Children's Hospital

    Little Rock, Arkansasno site contact published

  • Boston Children's Hospital

    Boston, Massachusettsno site contact published

  • Chiildren's Hospital of Philadelphia

    Philadelphia, Pennsylvaniano site contact published

  • Children's Health Specialty Center

    Dallas, Texasno site contact published

  • Children's Hospital of Colorado

    Aurora, Coloradono site contact published

  • Children's Hospital of The King's Daughters

    Norfolk, Virginiano site contact published

  • Children's Hospital Wisconsin

    Milwaukee, Wisconsinno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Received delandistrogene moxeparvovec for Duchenne muscular dystrophy in a previous clinical study.
Has (a) parent(s) or legal caregiver(s) or is ≥18 years of age and able to understand and comply with the study visit schedule and all other protocol requirements.

Exclusion

Not applicable

What this trial measures

  • Number of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)Up to 10 years